Matches in Wikidata for { <http://www.wikidata.org/entity/Q91976897> ?p ?o ?g. }
Showing items 1 to 67 of
67
with 100 items per page.
- Q91976897 description "2019 թվականի մայիսի 11-ին հրատարակված գիտական հոդված" @default.
- Q91976897 description "2019 മെയ് 11 നു പ്രസിദ്ധീകരിച്ച ശാസ്ത്ര ലേഖനം" @default.
- Q91976897 description "article scientifique publié en 2019" @default.
- Q91976897 description "artículu científicu espublizáu en mayu de 2019" @default.
- Q91976897 description "bài báo khoa học" @default.
- Q91976897 description "scientific article published on 11 May 2019" @default.
- Q91976897 description "wetenschappelijk artikel" @default.
- Q91976897 description "наукова стаття, опублікована 11 травня 2019" @default.
- Q91976897 name "Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial" @default.
- Q91976897 name "Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial" @default.
- Q91976897 type Item @default.
- Q91976897 label "Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial" @default.
- Q91976897 label "Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial" @default.
- Q91976897 prefLabel "Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial" @default.
- Q91976897 prefLabel "Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial" @default.
- Q91976897 P1433 Q91976897-DD0AD6F3-4399-401B-86C5-2482490D94B4 @default.
- Q91976897 P1476 Q91976897-F1372DD2-F90B-49CE-B6D5-330537C89E0A @default.
- Q91976897 P2093 Q91976897-0097EA08-0864-4B6A-A7A6-069199991829 @default.
- Q91976897 P2093 Q91976897-11E3F4BC-F75C-41BD-BF75-BD111B31AC91 @default.
- Q91976897 P2093 Q91976897-13D5FAC0-E333-4198-8575-F1756AE6A965 @default.
- Q91976897 P2093 Q91976897-4118BC86-E838-47E1-965B-022E88991336 @default.
- Q91976897 P2093 Q91976897-6ABC6E7F-7BD0-4A8C-A50C-61325F8057E7 @default.
- Q91976897 P2093 Q91976897-6FB6931E-3A6C-43DC-8525-F729F976DE3B @default.
- Q91976897 P2093 Q91976897-87AFC3F0-FC1E-4DE3-9E56-AA01F22AA279 @default.
- Q91976897 P2093 Q91976897-925C3569-92A7-43F3-BE25-BFA768153242 @default.
- Q91976897 P2093 Q91976897-A0C899D3-9842-40C0-9973-6CD7F848FFBE @default.
- Q91976897 P2093 Q91976897-AC6524C2-F1BF-4D10-8A71-071A89A1B37F @default.
- Q91976897 P2093 Q91976897-AD8977AC-8D67-4006-A418-C271A5E2D6F1 @default.
- Q91976897 P2093 Q91976897-AF52437B-BE6F-474B-A807-C93EB2D88CF0 @default.
- Q91976897 P2093 Q91976897-D556E877-D794-4E70-9A40-507FC91E0599 @default.
- Q91976897 P2093 Q91976897-DFFC6AD5-4D83-4036-AFF8-C332A3C1874A @default.
- Q91976897 P2093 Q91976897-F536EE07-E1DD-4999-8CF7-50B1493E9937 @default.
- Q91976897 P304 Q91976897-6737070A-77D3-4446-9221-00500C34323F @default.
- Q91976897 P31 Q91976897-501DAA63-8639-4793-9084-0F37E88F7DA5 @default.
- Q91976897 P356 Q91976897-133C3F69-64F2-445C-A54E-39E752FF7866 @default.
- Q91976897 P478 Q91976897-303DA943-49AB-48D1-942D-E4BA70FD0733 @default.
- Q91976897 P577 Q91976897-BEF34FE5-82A0-40F4-B2CB-322DB51C9537 @default.
- Q91976897 P698 Q91976897-C9188465-AA64-4A09-9B08-1F1BD6489A60 @default.
- Q91976897 P921 Q91976897-3CD19EDC-DCE2-4BDA-B48D-F9A1B5270EC8 @default.
- Q91976897 P921 Q91976897-72572D35-A6F1-4463-810D-EAAB187BF049 @default.
- Q91976897 P356 J.EJCA.2019.04.007 @default.
- Q91976897 P698 31082669 @default.
- Q91976897 P1433 Q332260 @default.
- Q91976897 P1476 "Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial" @default.
- Q91976897 P2093 "Celestia S Higano" @default.
- Q91976897 P2093 "Charles J Ryan" @default.
- Q91976897 P2093 "Christopher J Sweeney" @default.
- Q91976897 P2093 "Cindy Lu" @default.
- Q91976897 P2093 "Daniel H Shevrin" @default.
- Q91976897 P2093 "Désirée Deandreis" @default.
- Q91976897 P2093 "Emmanuel S Antonarakis" @default.
- Q91976897 P2093 "Heather A Jacene" @default.
- Q91976897 P2093 "Hubert Vesselle" @default.
- Q91976897 P2093 "Jorge A Carrasquillo" @default.
- Q91976897 P2093 "Karim Fizazi" @default.
- Q91976897 P2093 "Michael J Morris" @default.
- Q91976897 P2093 "Neeta Pandit-Taskar" @default.
- Q91976897 P2093 "Oana Petrenciuc" @default.
- Q91976897 P2093 "Yohann Loriot" @default.
- Q91976897 P304 "107-116" @default.
- Q91976897 P31 Q13442814 @default.
- Q91976897 P356 "10.1016/J.EJCA.2019.04.007" @default.
- Q91976897 P478 "114" @default.
- Q91976897 P577 "2019-05-11T00:00:00Z" @default.
- Q91976897 P698 "31082669" @default.
- Q91976897 P921 Q420436 @default.
- Q91976897 P921 Q5452194 @default.